<DOC>
	<DOCNO>NCT00020618</DOCNO>
	<brief_summary>RATIONALE : Morphine inhale may rapidly absorb morphine give mouth . It yet know inhaled morphine effective morphine give mouth relieve breakthrough pain . PURPOSE : Randomized phase II trial compare effectiveness inhale morphine morphine give mouth treat cancer patient breakthrough pain .</brief_summary>
	<brief_title>Inhaled Morphine Compared With Morphine By Mouth Treating Cancer Patients With Breakthrough Pain</brief_title>
	<detailed_description>OBJECTIVES : I . Compare change pain intensity 15 minute immediately follow aerosolize vs oral morphine sulfate cancer patient opioid-sensitive breakthrough pain . II . Compare preference continue use regimens patient . III . Compare pain relief patient treat regimen . IV . Evaluate satisfaction patient treat regimen . OUTLINE : This randomize , open-label , crossover , multicenter study . Patients randomize 1 2 treatment arm . Patients undergo titration aerosolize morphine sulfate day 1-7 determine optimal baseline breakthrough dosage . Arm I : Patients receive aerosolize morphine sulfate need breakthrough pain , 4 inhalation every 15 minute , day 8-14 . Patients crossover oral morphine sulfate need breakthrough pain day 15-21 . Arm II : Patients receive oral morphine sulfate need breakthrough pain day 8-14 . Patients crossover aerosolized morphine sulfate need breakthrough pain , 4 inhalation every 15 minute , day 15-21 . Patients may continue treatment either oral aerosolized morphine sulfate additional 60 day begin day 22 . Quality life assess weekly 3 week . Patients complete pain management satisfaction survey end therapy crossover week . PROJECTED ACCRUAL : Approximately 50 patient accrue study .</detailed_description>
	<mesh_term>Breakthrough Pain</mesh_term>
	<mesh_term>Morphine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Opioidsensitive breakthrough pain due cancer More 1 episode daily Oral opiate dose 100 mg morphine No known allergy morphine opioids No know CNS excitatory response morphine opioids No unstable persistent morbidity due prior chemotherapy radiotherapy PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 03 Life expectancy : More 3 month Hematopoietic : Not specify Hepatic : Bilirubin le 2.0 mg/dL AST le 82 U/L ALT le 72 U/L Renal : Creatinine le 1.5 mg/dL Pulmonary : No significant history recent exacerbation bronchial asthma No chronic obstructive pulmonary disease No significant pulmonary pathology would preclude study Other : No history substance abuse , include alcohol , within past 2 month No condition would preclude study Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Recovered prior chemotherapy No concurrent chemotherapy would cause toxicity ( e.g. , emesis ) Endocrine therapy : Not specify Radiotherapy : Recovered prior radiotherapy No concurrent radiotherapy would cause toxicity ( e.g. , emesis ) Surgery : Not specify Other : At least 30 day 5 halflives ( whichever longer ) since prior investigational drug No concurrent MAO inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2002</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>pain</keyword>
</DOC>